Skip to main content
. 2021 May 27;22(11):5707. doi: 10.3390/ijms22115707

Figure 2.

Figure 2

A Timeline of BTK and its inhibitor. BTK has made remarkable progress in the past 10 years in its treatment in a variety of B cell related malignancies and even more clinical trials are underway, including some in MM.